ADORA2A and neoplasm: By delivering an A2AR inhibitor to the tumor via PPDA, an adhesive nanocarrier with photothermal properties, we directly targeted the negative feedback generated from the adenosine‐A2AR metabolic pathway during the ICD process to alter the immunosuppressive TME.